Archive for December 2nd, 2009

In 2002 the National Institute for Clinical Excellence (NICE) ruled that certain drugs for the treatment of multiple sclerosis (MS) were not cost effective. In response, the Department of Health (DH) set up an observational study called the Risk Sharing Scheme…

In 2002 the National Institute for Clinical Excellence (NICE) ruled that certain drugs for the treatment of multiple sclerosis (MS) were not cost effective. In response, the Department of Health (DH) set up an observational study called the Risk Sharing Scheme…

In 2002 the National Institute for Clinical Excellence (NICE) ruled that certain drugs for the treatment of multiple sclerosis (MS) were not cost effective. In response, the Department of Health (DH) set up an observational study called the Risk Sharing Scheme…

Best-practice recommendations for the selection and management of patients with multiple sclerosis (MS) who may benefit from, or are receiving treatment with TYSABRI® (natalizumab) were published recently in a supplement to the medical journal Multiple Sclerosis. The panel provided recommendations focusing on appropriate patient selection and patient management…

Best-practice recommendations for the selection and management of patients with multiple sclerosis (MS) who may benefit from, or are receiving treatment with TYSABRI® (natalizumab) were published recently in a supplement to the medical journal Multiple Sclerosis. The panel provided recommendations focusing on appropriate patient selection and patient management…